We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GW’s Cannabis-based Candidate Shines in Phase 3
GW Pharmaceuticals’ cannabis-based Lennox-Gastaut syndrome treatment Epidiolex shined in a Phase 3 trial, reaching its primary endpoint of a significant reduction in the monthly frequency of atonic seizures compared to a placebo over a 14-week treatment period.